UB Paderborn / Katalog / Suche / in CDI

Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion

Cancer research (Chicago, Ill.), 2008-10, Vol.68 (20), p.8210-8220

2008

Volltextzugriff (PDF)

Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain Colonization

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8), p.1299-1314

2023

Volltextzugriff (PDF)

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-06-OT2-11-06

2022

Volltextzugriff (PDF)

Abstract P5-11-11: A preliminary assessment of knowledge, attitudes, and awareness surrounding ESR1 mutations and biomarker testing amongst medical oncologists

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-11-11

2019

Volltextzugriff (PDF)

Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice

Cancer research (Chicago, Ill.), 1992-12, Vol.52 (23), p.6553-6560

1992

Volltextzugriff (PDF)

Abstract P3-08-09: The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-09

2019

Volltextzugriff (PDF)

Abstract OT1-01-02: An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2 - breast cancer (MBC) with an ESR1 mutation

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-01-02-OT1-01-02

2019

Volltextzugriff (PDF)

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS5-24-PS5-24

2021

Volltextzugriff (PDF)

Abstract P5-04-04: Activation of ERβ in triple negative breast cancer results in cell cycle arrest

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-04-04

2017

Volltextzugriff (PDF)

Abstract 2145: Detect early tumor relapse in high-risk breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2145-2145

2019

Volltextzugriff (PDF)

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action

Cancer research (Chicago, Ill.), 1995-06, Vol.55 (11), p.2325-2333

1995

Volltextzugriff (PDF)

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS4-07-GS4-07

2019

Volltextzugriff (PDF)

Abstract P3-08-01: Characteristics, outcomes and prognostic factors of luminal androgen receptor (LAR) triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-01

2019

Volltextzugriff (PDF)

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-07-OT3-02-07

2019

Volltextzugriff (PDF)

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-08-OT3-02-08

2019

Volltextzugriff (PDF)

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-07

2018

Volltextzugriff (PDF)

Abstract P3-05-06: Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and its relation to stromal tumor infiltrating lymphocytes (sTILs) in triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-05-06

2018

Volltextzugriff (PDF)

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-02-GS4-02

2018

Volltextzugriff (PDF)

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-07-OT3-05-07

2018

Volltextzugriff (PDF)

Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.33-33

2009

Volltextzugriff (PDF)

Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-11-OT1-03-11

2016

Volltextzugriff (PDF)

Abstract P4-04-05: Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-04-05

2016

Volltextzugriff (PDF)

Abstract 1932: Phenylmethimazole decreases constitutively high basal levels of Interleukin 6 (IL-6) in a triple negative breast cancer cell line

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1932-1932

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion

Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain Colonization

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Abstract P5-11-11: A preliminary assessment of knowledge, attitudes, and awareness surrounding ESR1 mutations and biomarker testing amongst medical oncologists

Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice

Abstract P3-08-09: The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

Abstract OT1-01-02: An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2 - breast cancer (MBC) with an ESR1 mutation

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Abstract P5-04-04: Activation of ERβ in triple negative breast cancer results in cell cycle arrest

Abstract 2145: Detect early tumor relapse in high-risk breast cancer

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

Abstract P3-08-01: Characteristics, outcomes and prognostic factors of luminal androgen receptor (LAR) triple-negative breast cancer (TNBC)

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer

Abstract P3-05-06: Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and its relation to stromal tumor infiltrating lymphocytes (sTILs) in triple negative breast cancer (TNBC)

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium

Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

Abstract P4-04-05: Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes

Abstract 1932: Phenylmethimazole decreases constitutively high basal levels of Interleukin 6 (IL-6) in a triple negative breast cancer cell line

Aktive Filter

Suchergebnisse filtern